Opus Genetics (IRD) Accounts Payables (2021 - 2024)
Opus Genetics (IRD) has disclosed Accounts Payables for 8 consecutive years, with $1.9 million as the latest value for Q3 2023.
- On a quarterly basis, Accounts Payables rose 28.75% to $1.9 million in Q3 2023 year-over-year; TTM through Sep 2023 was $1.9 million, a 28.75% increase, with the full-year FY2022 number at $1.1 million, down 32.51% from a year prior.
- Accounts Payables was $1.9 million for Q3 2023 at Opus Genetics, down from $2.3 million in the prior quarter.
- In the past five years, Accounts Payables ranged from a high of $2.3 million in Q2 2023 to a low of $1.1 million in Q4 2022.
- A 3-year average of $1.7 million and a median of $1.6 million in 2022 define the central range for Accounts Payables.
- Peak YoY movement for Accounts Payables: crashed 32.51% in 2022, then soared 40.66% in 2023.
- Opus Genetics' Accounts Payables stood at $1.6 million in 2021, then plummeted by 32.51% to $1.1 million in 2022, then skyrocketed by 76.8% to $1.9 million in 2023.
- Per Business Quant, the three most recent readings for IRD's Accounts Payables are $1.9 million (Q3 2023), $2.3 million (Q2 2023), and $2.2 million (Q1 2023).